Who
Charles J. Casamento
Director
Company insider
Files Form 4 as: Director, Eton Pharmaceuticals; Director, Relmada Therapeutics; Director, GT Biopharma; Director, PaxMedica; Director, GridAI Technologies; Director, International Stem Cell; Director, Astex Pharmaceuticals; Director, Vivus.
In numbers
- Trades disclosed
- 244
- Buys
- 6
- Sells
- 21
- Bought
- $117K
- Sold
- $3.5M
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 8 Feb 2005
- Last trade
- 31 Jul 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 4 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,196 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,757 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,196 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,757 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —164,000 at $0.00 | filing |
| 4 Sep 2025filed 8 Sep 2025 | GTBP GT Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 3 Jan 2025filed 6 Jan 2025 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 22 Oct 2024filed 23 Oct 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Code G | —13,000 at $0.00 | filing |
| 9 Sep 2024filed 11 Sep 2024 | RLMD Relmada TherapeuticsBiotechnology | SEC FORM 4 Bought | $33K13,000 at $2.56 | filing |
| 24 May 2024filed 29 May 2024 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,976 at $0.00 | filing |
| 24 May 2024filed 29 May 2024 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —20,976 at $0.00 | filing |
| 12 Mar 2024filed 14 Mar 2024 | PaxMedica | SEC FORM 4 Code F | $684992 at $0.69 | filing |
| 13 Feb 2024filed 15 Feb 2024 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 29 Jan 2024filed 31 Jan 2024 | PaxMedica | SEC FORM 4 Code F | $7497 at $0.76 | filing |
| 2 Jan 2024filed 4 Jan 2024 | GRDX GridAI TechnologiesElectric Utilities & IPPs | SEC FORM 4 Code A | —19,633 at $0.00 | filing |
| 15 Dec 2023filed 19 Dec 2023 | RLMD Relmada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,522 at $0.00 | filing |
| 2 Oct 2023filed 4 Oct 2023 | PaxMedica | SEC FORM 4 Code F | $1,8956,536 at $0.29 | filing |
News
Eton (NASDAQ: ETON) secures LIBERVANT license with milestones up to $47.5 millionETON · themarketsdaily.com · 14 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmETON · manilatimes.net · 14 Oct 2026Comparing Cronos Group (NASDAQ:CRON) and Eton Pharmaceuticals (NASDAQ:ETON)ETON · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Charles J. Casamento; 3 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.